<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072293</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000339581</org_study_id>
    <secondary_id>IBCSG 23-01</secondary_id>
    <nct_id>NCT00072293</nct_id>
  </id_info>
  <brief_title>Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases</brief_title>
  <acronym>23-01</acronym>
  <official_title>A Randomized Trial Of Axillary Dissection Versus No Axillary Dissection For Patients With Clinically Node Negative Breast Cancer And Micrometastases In The Sentinel Node</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Surgery to remove lymph nodes in the armpit in patients with sentinel lymph node
      micrometastases may remove cancer cells that have spread from tumors in the breast. It is not
      yet known whether surgery to remove the primary tumor is more effective with or without
      axillary lymph node dissection.

      PURPOSE: This randomized phase III trial is studying surgery and axillary lymph node
      dissection to see how well they work compared to surgery alone in treating women with
      node-negative breast cancer and sentinel lymph node micrometastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare disease-free survival of women with clinically node-negative breast cancer with
           sentinel lymph node micrometastases treated with surgical resection with or without
           axillary dissection.

        -  Compare overall survival of patients treated with these regimens.

        -  Assess sites of recurrence, particularly reappearance of disease in the undissected
           axilla.

        -  Assess long-term surgical complications in patients treated with these regimens.

      OUTLINE: This is a multicenter study. Patients are stratified according to participating
      center, menopausal status (pre- vs postmenopausal), and preoperative sentinel node biopsy
      (yes vs no). Patients are followed every 4 months for 1 year, every 6 months for 4 years, and
      then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year Disease-Free Survival</measure>
    <time_frame>5-year estimate reported after a median follow-up of 60 months</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year Overall Survival</measure>
    <time_frame>5-year estimate reported after a median follow-up of 60 months</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site of Recurrence</measure>
    <time_frame>Reported after a median follow-up of 60 months</time_frame>
    <description>Site of recurrence of breast cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">931</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Axillary Dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Axillary Dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary lymph node dissection</intervention_name>
    <description>Axillary lymph node dissection</description>
    <arm_group_label>Axillary Dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No axillary lymph node dissection</intervention_name>
    <description>Therapeutic conventional surgery</description>
    <arm_group_label>No Axillary Dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and
             unifocal breast carcinoma

          -  Largest tumor lesion ≤ 5 cm

          -  Palpable or nonpalpable breast lesion

               -  Preoperative radioactive occult lesion localization, hook wire, or other method
                  of localization required for nonpalpable lesions

          -  Prior (preoperative) or planned (intraoperative) sentinel node biopsy required

               -  At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with
                  no extracapsular extension

          -  No clinical evidence of distant metastases

               -  No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI,
                  or CT scan, including the following:

                    -  Skeletal pain of unknown cause

                    -  Elevated alkaline phosphatase

                    -  Bone scan showing hot spots

          -  No palpable axillary lymph node(s)

          -  No Paget's disease without invasive cancer

          -  Hormone receptor status:

               -  Estrogen receptor and progesterone receptor known

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Sex

          -  Female

        Menopausal status

          -  Any status

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  See Disease Characteristics

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  No other prior or concurrent malignancy except the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Adequately treated carcinoma in situ of the cervix

               -  Adequately treated in situ melanoma

               -  Contralateral or ipsilateral carcinoma in situ of the breast

          -  No psychiatric, addictive, or other disorder that may compromise ability to give
             informed consent

          -  Geographically accessible for follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

        Other

          -  No prior systemic therapy for breast cancer

          -  More than 1 year since prior chemopreventive agent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viviana E. Galimberti</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Umberto Veronesi, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lismore Base Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Hospital - North Sydney</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Cancer Centre at Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverina Cancer Care Centre</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Institute for Cancer Research at Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital Cancer Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John of God Hospital - Bunbury</name>
      <address>
        <city>Bunbury</city>
        <state>Western Australia</state>
        <zip>6230</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horsholm Sygenus</name>
      <address>
        <city>Horsholm</city>
        <zip>2970</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bologna Medical School</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Alessandro Manzoni</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico H. San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>I-27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>2020</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology - Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23491275</url>
    <description>Abstract from paper published in Lancet Oncology, 2013</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <results_first_submitted>February 26, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2016</results_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>estrogen receptor-negative breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-negative breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Micrometastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Accrual began April 1, 2001 and closed February 28, 2010, after 934 patients from 27 centers in Europe, South America and Australia were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Axillary Dissection</title>
          <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
Axillary lymph node dissection: Axillary lymph node dissection</description>
        </group>
        <group group_id="P2">
          <title>No Axillary Dissection</title>
          <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
No axillary lymph node dissection: Therapeutic conventional surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="465"/>
                <participants group_id="P2" count="469"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>Axillary Dissection</title>
          <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
Axillary lymph node dissection: Axillary lymph node dissection</description>
        </group>
        <group group_id="B2">
          <title>No Axillary Dissection</title>
          <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
No axillary lymph node dissection: Therapeutic conventional surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="464"/>
            <count group_id="B2" value="467"/>
            <count group_id="B3" value="931"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="28" upper_limit="81"/>
                    <measurement group_id="B2" value="54" lower_limit="26" upper_limit="81"/>
                    <measurement group_id="B3" value="54" lower_limit="26" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="464"/>
                    <measurement group_id="B2" value="467"/>
                    <measurement group_id="B3" value="931"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>5-year Disease-Free Survival</title>
        <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.</description>
        <time_frame>5-year estimate reported after a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Axillary Dissection</title>
            <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
Axillary lymph node dissection: Axillary lymph node dissection</description>
          </group>
          <group group_id="O2">
            <title>No Axillary Dissection</title>
            <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
No axillary lymph node dissection: Therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Disease-Free Survival</title>
          <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.</description>
          <population>Intention-to-treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>As originally designed, target accrual was 1960 patients with analysis planned after 558 events. These targets were based on having 90% power to detect non-inferiority of no axillary dissection with a one-sided statistical signifi cance level of 10% (ie, α=0·10) under the assumption that 5-year disease-free survival with axillary dissection was 70% and defining non-inferiority as a hazard ratio (HR) of less than 1·25 (no axillary dissection relative to axillary dissection).</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>Test for non-inferiority of no axillary dissection. Stratified logrank test compared groups. HR (no-AD vs AD) estimated from test statistic and variance as HR=exp([O–E]/V), compared to 1.25 in 1-sided test of non-inferiority.</p_value_desc>
            <method>1-sided non-inferiority test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Hazard Ratio is no axillary dissection/axillary dissection.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Overall Survival</title>
        <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death of any cause.</description>
        <time_frame>5-year estimate reported after a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Axillary Dissection</title>
            <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
Axillary lymph node dissection: Axillary lymph node dissection</description>
          </group>
          <group group_id="O2">
            <title>No Axillary Dissection</title>
            <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
No axillary lymph node dissection: Therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Overall Survival</title>
          <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death of any cause.</description>
          <population>Intention-to-treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>Hazard Ratio is no axillary dissection/axillary dissection.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Site of Recurrence</title>
        <description>Site of recurrence of breast cancer</description>
        <time_frame>Reported after a median follow-up of 60 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Axillary Dissection</title>
            <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
Axillary lymph node dissection: Axillary lymph node dissection</description>
          </group>
          <group group_id="O2">
            <title>No Axillary Dissection</title>
            <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
No axillary lymph node dissection: Therapeutic conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Site of Recurrence</title>
          <description>Site of recurrence of breast cancer</description>
          <population>Intention-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regional recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contralateral breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distant recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second (non-breast) primary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death without cancer event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5-years. Treating physician assessed and reported long-term surgical events (sensory neuropathy, lymphoedema and motor neuropathy) at every follow-up visit (every 4 months from date of randomization for the first year and every six months from years 2-5).</time_frame>
      <desc>Analysis population excludes 31 patients (17 in Axillary Dissection group/14 in No Axillary Dissection group) who did not receive the randomly-assigned treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Axillary Dissection</title>
          <description>Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
Axillary lymph node dissection: Axillary lymph node dissection</description>
        </group>
        <group group_id="E2">
          <title>No Axillary Dissection</title>
          <description>Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
No axillary lymph node dissection: Therapeutic conventional surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post−operative infection (L.axilla)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="453"/>
              </event>
              <event>
                <sub_title>Motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="453"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rudolf Maibach, Executive Officer for International Trial Activities</name_or_title>
      <organization>IBCSG</organization>
      <phone>+41 31 389 91 96</phone>
      <email>rudolf.maibach@ibcsg.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

